Summary of proceedings of the 36th Annual General Meeting of the Shareholders held at 10 AM through video conferencing mode.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venmax Drugs and Pharmaceuticals held its 36th AGM on September 27, 2025, at 10:00 AM via video conferencing, with 45 members present. The Chairman, Mr. Venkata Rao Sadhanala, briefed shareholders on the company's business operations, financial performance for FY 2024-25, and future outlook. Five ordinary resolutions were put forward for member approval, including adoption of audited financial statements, reappointment of a retiring director, regularization of a new independent director, appointment of a secretarial auditor, and an increase in authorised share capital with a corresponding amendment to the Memorandum of Association. E-voting was conducted through CDSL, with results to be filed with BSE within the stipulated timeline. The meeting concluded at 10:30 AM.
For shareholders, the key items to watch are the authorised share capital increase (which could pave the way for a future fund raise or stock split) and the induction of a new independent director, Mrs. Dakshita Jain. The actual voting results and financial details are still awaited and could be a near-term catalyst for the stock.